The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Insights into an oncology simulation model being used to evaluate treatment regimens in HL
In this video, Tycel Phillips, MD, City of Hope, Duarte, CA, gives an overview of an oncology simulation model being used to evaluate the impact of brentuximab vedotin in the treatment of patients with Hodgkin lymphoma (HL) based on data from the ECHELON-1 trial (NCT01712490). This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
